PE20170073A1 - Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd - Google Patents
Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copdInfo
- Publication number
- PE20170073A1 PE20170073A1 PE2016002160A PE2016002160A PE20170073A1 PE 20170073 A1 PE20170073 A1 PE 20170073A1 PE 2016002160 A PE2016002160 A PE 2016002160A PE 2016002160 A PE2016002160 A PE 2016002160A PE 20170073 A1 PE20170073 A1 PE 20170073A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- copd
- lama
- formoterol
- budesonide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un producto de combinacion que comprende: (a) una primera composicion inhalable de un antagonista muscarinico de accion prolongada (LAMA); y (b) una segunda composicion de dosis fija inhalable que comprende budesonida y formoterol o una sal farmaceuticamente aceptable del mismo. El LAMA puede ser tiotropio, bromuro de aclidinio o glicopirrolato, siendo tiotropio el mas preferido. Dicho producto de combinacion es util en el tratamiento de la enfermedad pulmonar obstructiva cronica (COPD) en pacientes que requieren tratamiento a largo plazo con LAMA, en las cuales la segunda composicion es administrada por razones necesarias (pro re nata) como una medicacion de rescate para el tratamiento de las exacerbaciones agudas de la COPD
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1408387.7A GB201408387D0 (en) | 2014-05-12 | 2014-05-12 | Treatment of respiratory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170073A1 true PE20170073A1 (es) | 2017-03-24 |
Family
ID=51032625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016002160A PE20170073A1 (es) | 2014-05-12 | 2015-05-08 | Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd |
Country Status (17)
Country | Link |
---|---|
US (2) | US20170202858A1 (es) |
EP (2) | EP3142653A1 (es) |
JP (4) | JP2017515835A (es) |
KR (2) | KR20170003601A (es) |
CN (2) | CN106470700A (es) |
AR (2) | AR100369A1 (es) |
AU (2) | AU2015261103A1 (es) |
BR (2) | BR112016026369A2 (es) |
CA (2) | CA2948574A1 (es) |
CL (1) | CL2016002848A1 (es) |
EA (2) | EA201692276A1 (es) |
GB (1) | GB201408387D0 (es) |
IL (2) | IL248875A0 (es) |
MX (2) | MX2016014695A (es) |
PE (1) | PE20170073A1 (es) |
UA (2) | UA119774C2 (es) |
WO (2) | WO2015173154A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758294A (zh) * | 2014-12-17 | 2015-07-08 | 广州呼吸疾病研究所 | 用于copd、哮喘治疗的吸入药物组合物及其制备方法 |
TW201735914A (zh) * | 2015-12-22 | 2017-10-16 | 阿斯特捷利康公司 | 用於治療慢性阻塞性肺疾病之醫藥組成物 |
CN106466322A (zh) * | 2016-08-25 | 2017-03-01 | 杭州百诚医药科技股份有限公司 | 一种以布***和噻托溴铵为活性成分的复方制剂 |
WO2018071435A1 (en) * | 2016-10-11 | 2018-04-19 | Microdose Therapeutx, Inc. | Inhaler and methods of use thereof |
WO2019142214A1 (en) | 2018-01-19 | 2019-07-25 | Cipla Limited | Pharmaceutical composition comprising tiotropium for inhalation |
MX2020008717A (es) * | 2018-02-23 | 2020-12-07 | Microdose Therapeutx Inc | Inhalador y metodos de uso del mismo. |
CN116077471A (zh) * | 2021-11-08 | 2023-05-09 | 上海臣邦医药科技股份有限公司 | 一种供吸入用的粉雾剂组合物及其制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0613371B1 (en) * | 1991-12-18 | 2002-03-06 | AstraZeneca AB | New combination of formoterol and budesonide |
JP3342484B2 (ja) * | 1991-12-18 | 2002-11-11 | アストラ・アクチエボラーグ | 新規な配合 |
SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
SE9802073D0 (sv) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
UA80123C2 (en) * | 2002-04-09 | 2007-08-27 | Boehringer Ingelheim Pharma | Inhalation kit comprising inhalable powder of tiotropium |
SE526509C2 (sv) * | 2003-06-19 | 2005-09-27 | Microdrug Ag | Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd |
US20070293460A1 (en) * | 2005-10-31 | 2007-12-20 | Richie's Pharmacy And Medical Supply, Incorporated | Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease |
WO2008021142A2 (en) * | 2006-08-09 | 2008-02-21 | Glaxo Group Limited | Process for manufacturing lactose |
KR20090121338A (ko) * | 2007-02-19 | 2009-11-25 | 씨아이피엘에이 엘티디. | 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합 |
RU2010108640A (ru) * | 2007-09-12 | 2011-10-20 | Глаксо Груп Лимитед (GB) | Новая комбинация терапевтических агентов |
TR201000680A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler |
SI2560611T1 (en) * | 2010-04-21 | 2018-03-30 | Chiesi Farmaceutici S.P.A. | A process for preparing particles with reduced electrostatic charges |
NZ605920A (en) * | 2010-07-16 | 2015-01-30 | Cipla Ltd | Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators |
JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
RU2460547C1 (ru) * | 2011-04-08 | 2012-09-10 | Валерий Феофанович Ушаков | Способ пролонгированной профилактики холодового бронхоспазма у больных с "микст-патологией" |
WO2014007770A2 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising corticosteroid and sorbitol |
ITMI20130571A1 (it) * | 2013-04-10 | 2014-10-11 | Zambon Spa | Composizione farmaceutica contenente budesonide e formoterolo |
-
2014
- 2014-05-12 GB GBGB1408387.7A patent/GB201408387D0/en not_active Ceased
-
2015
- 2015-05-08 AU AU2015261103A patent/AU2015261103A1/en not_active Abandoned
- 2015-05-08 JP JP2016567354A patent/JP2017515835A/ja active Pending
- 2015-05-08 UA UAA201612511A patent/UA119774C2/uk unknown
- 2015-05-08 CA CA2948574A patent/CA2948574A1/en not_active Abandoned
- 2015-05-08 US US15/310,133 patent/US20170202858A1/en not_active Abandoned
- 2015-05-08 JP JP2016567345A patent/JP2017515833A/ja active Pending
- 2015-05-08 BR BR112016026369-3A patent/BR112016026369A2/pt not_active Application Discontinuation
- 2015-05-08 EA EA201692276A patent/EA201692276A1/ru unknown
- 2015-05-08 US US15/310,130 patent/US20170209464A1/en not_active Abandoned
- 2015-05-08 KR KR1020167033456A patent/KR20170003601A/ko not_active Application Discontinuation
- 2015-05-08 MX MX2016014695A patent/MX2016014695A/es unknown
- 2015-05-08 WO PCT/EP2015/060257 patent/WO2015173154A1/en active Application Filing
- 2015-05-08 EP EP15722174.8A patent/EP3142653A1/en not_active Withdrawn
- 2015-05-08 PE PE2016002160A patent/PE20170073A1/es unknown
- 2015-05-08 CA CA2948553A patent/CA2948553A1/en not_active Abandoned
- 2015-05-08 EA EA201692278A patent/EA201692278A1/ru unknown
- 2015-05-08 BR BR112016026371-5A patent/BR112016026371A2/pt not_active Application Discontinuation
- 2015-05-08 KR KR1020167033449A patent/KR20170003600A/ko not_active Application Discontinuation
- 2015-05-08 EP EP15723675.3A patent/EP3142654A1/en not_active Withdrawn
- 2015-05-08 MX MX2016014696A patent/MX2016014696A/es unknown
- 2015-05-08 CN CN201580027124.1A patent/CN106470700A/zh active Pending
- 2015-05-08 UA UAA201612510A patent/UA119773C2/uk unknown
- 2015-05-08 WO PCT/EP2015/060256 patent/WO2015173153A1/en active Application Filing
- 2015-05-08 AU AU2015261104A patent/AU2015261104A1/en not_active Abandoned
- 2015-05-08 CN CN201580024895.5A patent/CN106488770A/zh active Pending
- 2015-05-11 AR ARP150101432A patent/AR100369A1/es unknown
- 2015-05-11 AR ARP150101431A patent/AR100368A1/es unknown
-
2016
- 2016-11-09 IL IL248875A patent/IL248875A0/en unknown
- 2016-11-09 CL CL2016002848A patent/CL2016002848A1/es unknown
- 2016-11-09 IL IL248874A patent/IL248874A0/en unknown
-
2019
- 2019-10-11 JP JP2019187349A patent/JP2020023536A/ja not_active Withdrawn
- 2019-10-11 JP JP2019187350A patent/JP2020023537A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170073A1 (es) | Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd | |
CY1123391T1 (el) | (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι | |
BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
PH12017502087A1 (en) | Tiotropium inhalation solution for nebulization | |
BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
WO2014064410A3 (en) | Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane | |
TR201000680A2 (tr) | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler | |
TR201000623A2 (tr) | Yeni tiotropyum kombinasyonu. | |
DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
AR100784A1 (es) | Micropartículas multicomponentes para usar en una formulación inhalable, proceso para preparar, formulación farmacéutica, inhalador | |
TR201000622A2 (tr) | Tiotropyum içeren farmasötik kombinasyonlar. | |
BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
EA201201397A1 (ru) | Ингалятор, содержащий расслаиваемую блистерную упаковку | |
EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
AR094063A1 (es) | Uso de aclidinio, composicion farmaceutica y metodo para mejorar la actividad fisica en pacientes respiratorios | |
BR112018072177A2 (pt) | composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta | |
EA201201394A1 (ru) | Ингалятор для доставки лекарственного средства в виде сухого порошка | |
JP2015533131A5 (es) | ||
Bostock-Cox | Masterclass: using combination inhalers in COPD. | |
Zhou et al. | A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Safety And Efficacy Of Vilanterol And Fluticasone Furoate/vilanterol In The Treatment Of Asthma: A Systematic Review And Meta-Analysis | |
EA201891911A1 (ru) | Применение тамоксифена для лечения кистозного фиброза у пациентов обоих полов | |
Malhotra | Facial oedema: 2 case reports | |
AR102304A1 (es) | Formulación inhalable |